Back Pain News and Research

Latest Back Pain News and Research

Exercise, nutrition and hormone optimization are key to improve men's health issues

Grant Mansell was 46 and frustrated with his 300 pound physique, ensuing back pain, rising cholesterol, dependency on blood pressure medicine but most of all not enjoying life with his wife and children.

8 Jan 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

ESS improves quality of life in CRS patients

Upwards of 76 percent of patients with chronic rhinosinusitis (CRS) experienced significant quality of life (QOL) improvements after undergoing endoscopic sinus surgery (ESS), according to new research in the January 2010 issue of Otolaryngology - Head and Neck Surgery.

3 Jan 2010

TENS therapy is not effective against chronic low-back pain

A new guideline issued by the American Academy of Neurology finds that transcutaneous electric nerve stimulation (TENS), a widely used pain therapy involving a portable device, is not recommended to treat chronic low-back pain that has persisted for three months or longer because research shows it is not effective.

31 Dec 2009

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

Back pain problems continue to rise in U.S.

The Bonati Spine Institute, the leader in minimally invasive laser spine surgery, reports the results of studies that Americans are increasingly reporting back pain and spending more on back pain, but cautions consumers to carefully research the experience and the surgical outcome results when choosing their spine team.

23 Dec 2009

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Emisphere Technologies, Inc. today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.

22 Dec 2009

Medtronic launches its SOVEREIGN Spinal System in the U.S.

Medtronic, Inc. today announced the U.S. launch of the SOVEREIGN™ Spinal System.

18 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

Interleukin Genetics introduces the Bone Health Genetic Test

Interleukin Genetics, Inc. announced today availability of the Bone Health Genetic Test designed to detect genetic patterns associated with the development of osteoporosis-related outcomes. The test determines an individual's risk for developing vertebral or spinal fractures and low bone mineral density.

17 Dec 2009

ASA offers practical ways for sufferers to take active role in treatment of pain

Whether the result of injury, illness or a chronic condition, 70 million Americans experience pain annually. The individual pain sufferer may experience a diminished quality of life, lack of mobility and added stress.

17 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Pharmacy directors willing to cover tanezumab at lower prices

HealthLeaders-InterStudy and Fingertip Formulary find that 70 percent of surveyed pharmacy directors expect to cover Pfizer's tanezumab if it is approved for the treatment of chronic pain. Tanezumab, which is expected to be the first biologic approved for chronic pain and is administered intravenously under medical supervision, will likely be covered as a medical benefit rather than a pharmacy benefit according to surveyed pharmacy directors.

16 Dec 2009

Pillo1 for chronic neck and back pain

At a time when Americans spend over $50 billion on ways to alleviate neck and back pain, Dr. Raymond Hall is theorizing a painful connection between conventional pillows and neck issues and created a revolutionary solution called Pillo1 (www.pillo1.com) to address the problem.

16 Dec 2009

Spinal Restoration receives FDA SPA concurrence letter for its Phase 3 Biostat System study

Spinal Restoration, Inc. announced today it has received a Special Protocol Assessment concurrence letter from the U.S. Food and Drug Administration (FDA) for the design of its Phase 3 study of the Biostat System for the treatment of chronic discogenic low back pain.

15 Dec 2009

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Genentech announces positive results from Phase II study of T-DM1

Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.

14 Dec 2009

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710).

14 Dec 2009

Back Pain News and Research

Latest Back Pain News and Research

Exercise, nutrition and hormone optimization are key to improve men's health issues

VELCADE sNDA receives FDA approval

ESS improves quality of life in CRS patients

TENS therapy is not effective against chronic low-back pain

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Back pain problems continue to rise in U.S.

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Medtronic launches its SOVEREIGN Spinal System in the U.S.

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Interleukin Genetics introduces the Bone Health Genetic Test

ASA offers practical ways for sufferers to take active role in treatment of pain

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Pharmacy directors willing to cover tanezumab at lower prices

Pillo1 for chronic neck and back pain

Spinal Restoration receives FDA SPA concurrence letter for its Phase 3 Biostat System study

ZYPREXA RELPREVV approved by FDA

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech announces positive results from Phase II study of T-DM1

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Back Pain News and Research

Latest Back Pain News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in